The securities represent 8,835,440 shares of common stock, $0.0001 par value per share (the "Common Stock") issuable upon conversion of 220,886 shares of Series A Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), held directly by Fairmount Healthcare Fund II L.P. ("Fund II"). The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%. Row 13 is based on 96,572,019 shares of Common Stock outstanding as of June 23, 2026, consisting of (i) 86,841,253 shares of Common Stock outstanding as of April 28, 2026, as reported in the Company's Form 10-Q filed on May 5, 2026, (ii) 666,680 shares of Common Stock issued upon the June 23, 2026 conversion by Fund II of 16,667 shares of the Series B Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock") (iii) 228,646 shares underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by the Reporting Persons and (iv) 8,835,440 shares of Common Stock underlying the 220,886 shares of Series A Preferred Stock owned by Fund II, applying the beneficial ownership limitation.

The securities represent 8,835,440 shares of Common Stock issuable upon conversion of 220,886 shares of Series A Preferred Stock held directly by Fund II. The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%. Row 13 is based on 96,572,019 shares of Common Stock outstanding as of June 23, 2026, consisting of (i) 86,841,253 shares of Common Stock outstanding as of April 28, 2026, as reported in the Company's Form 10-Q filed on May 5, 2026, (ii) 666,680 shares of Common Stock issued upon the June 23, 2026 conversion by Fund II of 16,667 shares of the Series B Preferred Stock (iii) 228,646 shares underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by the Reporting Persons and (iv) 8,835,440 shares of Common Stock underlying the 220,886 shares of Series A Preferred Stock owned by Fund II, applying the beneficial ownership limitation.

The securities include (a) 406,038 shares of Common Stock held directly by Mr. Harwin, (b) 114,323 shares of Common Stock issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days of the date of this filing held directly by Mr. Harwin*, and (c) Fund II's direct holdings of 9,146,840 shares of Common Stock issuable upon conversion of 228,671 shares of Series A Preferred Stock held directly by Fund II. The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%. Row 13 is based on 96,769,096 shares of Common Stock outstanding as of June 23, 2026, consisting of (i) 86,841,253 shares of Common Stock outstanding as of April 28, 2026, as reported in the Company's Form 10-Q filed on May 5, 2026, (ii) 666,680 shares of Common Stock issued upon the June 23, 2026 conversion by Fund II of 16,667 shares of the Series B Preferred Stock, (iii) 114,323 shares of Common Stock underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by Mr. Harwin and (iii) 9,146,840 shares of Common Stock underlying the 228,671 shares of Series A Preferred Stock owned by Fund II, applying the beneficial ownership limitation. * Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

The securities include (a) 406,038 shares of Common Stock held directly by Mr. Kiselak, (b) 114,323 shares of Common Stock issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days of the date of this filing held directly by Mr. Kiselak*, and (c) Fund II's direct holdings of 9,146,840 shares of Common Stock issuable upon conversion of 228,671 shares of Series A Preferred Stock held directly by Fund II. The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%. Row 13 is based on 96,769,096 shares of Common Stock outstanding as of June 23, 2026, consisting of (i) 86,841,253 shares of Common Stock outstanding as of April 28, 2026, as reported in the Company's Form 10-Q filed on May 5, 2026, (ii) 666,680 shares of Common Stock issued upon the June 23, 2026 conversion by Fund II of 16,667 shares of the Series B Preferred Stock, (iii) 114,323 shares of Common Stock underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by Mr. Harwin and (iii) 9,146,840 shares of Common Stock underlying the 228,671 shares of Series A Preferred Stock owned by Fund II, applying the beneficial ownership limitation. * Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.